Form 8-K - Current report:
SEC Accession No. 0001104659-22-059889
Filing Date
2022-05-13
Accepted
2022-05-13 08:30:22
Documents
12
Period of Report
2022-05-12
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2215399d1_8k.htm   iXBRL 8-K 34548
  Complete submission text file 0001104659-22-059889.txt   208489

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ruby-20220512.xsd EX-101.SCH 3033
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ruby-20220512_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ruby-20220512_pre.xml EX-101.PRE 22595
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2215399d1_8k_htm.xml XML 3607
Mailing Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139
Business Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139 617-679-9600
Rubius Therapeutics, Inc. (Filer) CIK: 0001709401 (see all company filings)

EIN.: 042688109 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38586 | Film No.: 22920355
SIC: 2836 Biological Products, (No Diagnostic Substances)